©aquir / 123RF Stock Photo

FDA approved a broadened indication of afatinib in the 1st-line treatment of metastatic NSCLC with non-resistant EGFR mutations

/0 Comments/in /by

 

 

You might also like
Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Vemurafenib FDA approved for treatment of Erdheim-Chester Disease with BRAF V600 mutation
PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive GEP-NETs
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018 Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Everolimus suspension approved in TSC-associated partial-onset seizures
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply